Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | GERN |
---|---|---|
09:32 ET | 88438 | 4.78 |
09:34 ET | 25796 | 4.77 |
09:36 ET | 13872 | 4.7797 |
09:38 ET | 16264 | 4.7975 |
09:39 ET | 14437 | 4.8 |
09:41 ET | 7631 | 4.805 |
09:43 ET | 138966 | 4.78 |
09:45 ET | 10925 | 4.805 |
09:48 ET | 11515 | 4.805 |
09:50 ET | 34720 | 4.805 |
09:52 ET | 10261 | 4.785 |
09:54 ET | 17723 | 4.78 |
09:56 ET | 10827 | 4.8 |
09:57 ET | 35218 | 4.8 |
09:59 ET | 15019 | 4.79 |
10:01 ET | 49490 | 4.775 |
10:03 ET | 29406 | 4.77 |
10:06 ET | 17874 | 4.77 |
10:08 ET | 22104 | 4.77 |
10:10 ET | 51877 | 4.745 |
10:12 ET | 40749 | 4.745 |
10:14 ET | 11438 | 4.745 |
10:15 ET | 44943 | 4.735 |
10:17 ET | 9074 | 4.7422 |
10:19 ET | 105229 | 4.725 |
10:21 ET | 52301 | 4.71 |
10:24 ET | 28672 | 4.695 |
10:26 ET | 32151 | 4.7012 |
10:28 ET | 10582 | 4.695 |
10:30 ET | 38556 | 4.695 |
10:32 ET | 22660 | 4.7 |
10:33 ET | 3490 | 4.7 |
10:35 ET | 45113 | 4.715 |
10:37 ET | 9806 | 4.72 |
10:39 ET | 12021 | 4.72 |
10:42 ET | 29466 | 4.6899 |
10:44 ET | 31626 | 4.67 |
10:46 ET | 275528 | 4.64 |
10:48 ET | 171232 | 4.6199 |
10:50 ET | 286637 | 4.59 |
10:51 ET | 108772 | 4.606 |
10:53 ET | 139901 | 4.59 |
10:55 ET | 32401 | 4.5894 |
10:57 ET | 346534 | 4.56 |
11:00 ET | 46442 | 4.555 |
11:02 ET | 57332 | 4.555 |
11:04 ET | 32304 | 4.575 |
11:06 ET | 53369 | 4.58 |
11:08 ET | 33512 | 4.57 |
11:09 ET | 10169 | 4.565 |
11:11 ET | 2542 | 4.565 |
11:13 ET | 53228 | 4.565 |
11:15 ET | 34628 | 4.57 |
11:18 ET | 18861 | 4.57 |
11:20 ET | 20749 | 4.575 |
11:22 ET | 8313 | 4.575 |
11:24 ET | 34408 | 4.555 |
11:26 ET | 13775 | 4.575 |
11:27 ET | 33111 | 4.57 |
11:29 ET | 12922 | 4.575 |
11:31 ET | 3976 | 4.57 |
11:33 ET | 315580 | 4.565 |
11:36 ET | 13375 | 4.55 |
11:38 ET | 8686 | 4.55 |
11:40 ET | 185404 | 4.595 |
11:42 ET | 42065 | 4.58 |
11:44 ET | 75734 | 4.6 |
11:45 ET | 118541 | 4.595 |
11:47 ET | 4904 | 4.595 |
11:49 ET | 27199 | 4.61 |
11:51 ET | 64237 | 4.605 |
11:54 ET | 8008 | 4.6 |
11:56 ET | 5415 | 4.6012 |
11:58 ET | 32593 | 4.655 |
12:00 ET | 12016 | 4.66 |
12:02 ET | 30821 | 4.64 |
12:03 ET | 8905 | 4.635 |
12:05 ET | 3059 | 4.64 |
12:07 ET | 52746 | 4.655 |
12:09 ET | 30915 | 4.655 |
12:12 ET | 54130 | 4.655 |
12:14 ET | 19089 | 4.675 |
12:16 ET | 12012 | 4.695 |
12:18 ET | 15681 | 4.715 |
12:20 ET | 14891 | 4.71 |
12:21 ET | 45159 | 4.725 |
12:23 ET | 93478 | 4.705 |
12:25 ET | 107573 | 4.695 |
12:27 ET | 3450 | 4.69 |
12:30 ET | 24094 | 4.685 |
12:32 ET | 6016 | 4.685 |
12:34 ET | 6962 | 4.685 |
12:36 ET | 15252 | 4.695 |
12:38 ET | 3370 | 4.695 |
12:39 ET | 10498 | 4.695 |
12:41 ET | 1021 | 4.695 |
12:43 ET | 7395 | 4.705 |
12:45 ET | 25422 | 4.695 |
12:48 ET | 3741 | 4.7 |
12:50 ET | 9382 | 4.685 |
12:52 ET | 5094 | 4.685 |
12:54 ET | 8604 | 4.685 |
12:56 ET | 14462 | 4.695 |
12:57 ET | 21563 | 4.6975 |
12:59 ET | 2300 | 4.695 |
01:01 ET | 31730 | 4.675 |
01:03 ET | 47841 | 4.655 |
01:06 ET | 17900 | 4.655 |
01:08 ET | 5877 | 4.655 |
01:10 ET | 16916 | 4.665 |
01:12 ET | 23081 | 4.675 |
01:14 ET | 25820 | 4.66 |
01:15 ET | 10426 | 4.66 |
01:17 ET | 17806 | 4.665 |
01:19 ET | 18894 | 4.675 |
01:21 ET | 17571 | 4.7 |
01:24 ET | 14431 | 4.695 |
01:26 ET | 13771 | 4.695 |
01:28 ET | 13722 | 4.69 |
01:30 ET | 4926 | 4.695 |
01:32 ET | 8690 | 4.69 |
01:33 ET | 5056 | 4.69 |
01:35 ET | 32629 | 4.67 |
01:37 ET | 12001 | 4.68 |
01:39 ET | 21010 | 4.675 |
01:42 ET | 12030 | 4.675 |
01:44 ET | 12538 | 4.675 |
01:46 ET | 18613 | 4.675 |
01:48 ET | 3001 | 4.68 |
01:50 ET | 7102 | 4.675 |
01:51 ET | 37566 | 4.655 |
01:53 ET | 8840 | 4.66 |
01:55 ET | 19805 | 4.665 |
01:57 ET | 26546 | 4.665 |
02:00 ET | 12564 | 4.65 |
02:02 ET | 4300 | 4.66 |
02:04 ET | 12583 | 4.665 |
02:06 ET | 14842 | 4.665 |
02:08 ET | 25067 | 4.655 |
02:09 ET | 7937 | 4.655 |
02:11 ET | 16491 | 4.66 |
02:13 ET | 15577 | 4.65 |
02:15 ET | 13990 | 4.655 |
02:18 ET | 140460 | 4.69 |
02:20 ET | 17131 | 4.6799 |
02:22 ET | 13386 | 4.675 |
02:24 ET | 15030 | 4.68 |
02:26 ET | 17323 | 4.68 |
02:27 ET | 12661 | 4.705 |
02:29 ET | 13601 | 4.71 |
02:31 ET | 7588 | 4.715 |
02:33 ET | 22578 | 4.725 |
02:36 ET | 5158 | 4.725 |
02:38 ET | 16620 | 4.735 |
02:40 ET | 5437 | 4.735 |
02:42 ET | 4100 | 4.735 |
02:44 ET | 159626 | 4.71 |
02:45 ET | 16933 | 4.715 |
02:47 ET | 16486 | 4.715 |
02:49 ET | 19669 | 4.712 |
02:51 ET | 4144 | 4.715 |
02:54 ET | 6828 | 4.715 |
02:56 ET | 23668 | 4.715 |
02:58 ET | 11011 | 4.715 |
03:00 ET | 8610 | 4.72 |
03:02 ET | 3589 | 4.71 |
03:03 ET | 16439 | 4.715 |
03:05 ET | 45262 | 4.715 |
03:07 ET | 10994 | 4.715 |
03:09 ET | 14846 | 4.705 |
03:12 ET | 2500 | 4.7 |
03:14 ET | 19051 | 4.695 |
03:16 ET | 53171 | 4.695 |
03:18 ET | 10967 | 4.695 |
03:20 ET | 22865 | 4.705 |
03:21 ET | 61384 | 4.705 |
03:23 ET | 19988 | 4.715 |
03:25 ET | 8634 | 4.715 |
03:27 ET | 10163 | 4.715 |
03:30 ET | 71031 | 4.715 |
03:32 ET | 31753 | 4.705 |
03:34 ET | 13505 | 4.7 |
03:36 ET | 21187 | 4.715 |
03:38 ET | 37409 | 4.7 |
03:39 ET | 12133 | 4.7 |
03:41 ET | 6967 | 4.705 |
03:43 ET | 144267 | 4.715 |
03:45 ET | 62668 | 4.705 |
03:48 ET | 38983 | 4.705 |
03:50 ET | 33270 | 4.715 |
03:52 ET | 124096 | 4.725 |
03:54 ET | 531308 | 4.74 |
03:56 ET | 371259 | 4.72 |
03:57 ET | 229436 | 4.7 |
03:59 ET | 250221 | 4.71 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Geron Corp | 2.8B | -13.6x | --- |
Morphic Holding Inc | 2.8B | -16.0x | --- |
Apogee Therapeutics Inc | 2.8B | -23.5x | --- |
MoonLake Immunotherapeutics | 3.0B | -61.9x | --- |
Celldex Therapeutics Inc | 2.6B | -14.0x | --- |
Structure Therapeutics Inc | 2.5B | -18.9x | --- |
Geron Corporation is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies. The Company is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes. It is developing imetelstat for the treatment of several myeloid hematologic malignancies, including a Phase 3 clinical trial, named IMpactMF, in relapsed/refractory myelofibrosis (MF) with overall survival as the primary endpoint, that is enrolling patients. It is also conducting a Phase 1 combination therapy clinical trial, named IMproveMF, in first-line Intermediate-1, Intermediate-2 or High-Risk myelofibrosis, or frontline MF, that is enrolling patients and imetelstat is being studied in an investigator-led Phase 2 clinical trial, named IMpress, in Intermediate-2 or High-Risk myelodysplastic syndromes and acute myeloid leukemia.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.8B |
---|---|
Revenue (TTM) | $520.0K |
Shares Outstanding | 593.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.48 |
EPS | $-0.35 |
Book Value | $0.46 |
P/E Ratio | -13.6x |
Price/Sales (TTM) | 5,372.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -40,381.92% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.